Can we incorporate MRD assessment into clinical practice in AML?

Publication date: Available online 10 May 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Gert Ossenkoppele, Gerrit Jan Schuurhuis, Arjan van de Loosdrecht, Jacqueline CloosAbstractMeasurable residual disease (MRD) can be assessed either by flow cytometry or molecular techniques. It has been proven to be highly prognostic in quite a number of prospective clinical studies. The recently published ELN MRD recommendations aim harmonize the approaches to MRD assessment in order to improve its overall quality. The predictive value leading to the usage as a surrogate endpoint for survival which would be instrumental for faster drug approvals has still to be proven. Nevertheless, many AML centers use MRD status to inform treatment.

Source: Best Practice and Research Clinical Haematology - May 11, 2019 Category: Hematology Source Type: research